The incremental prognostic value of admission measurements of biomarkers beyond clinical characteristics and extent of coronary artery disease ( CAD ) in patients treated with primary percutaneous coronary intervention ( PPCI ) for ST-elevation myocardial infarction ( STEMI ) is unclear .